Search

Your search keyword '"Orsini D"' showing total 301 results
Start Over Author "Orsini D"
301 results on '"Orsini D"'

3. Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study - IL PSO (Italian Landscape Psoriasis)

Author

Orsini, D, Megna, M, Assorgi, C, Balato, A, Balestri, R, Bernardini, N, Bettacchi, A, Bianchelli, T, Bianchi, L, Buggiani, G, Burlando, M, Brunasso, A, Caldarola, G, Cameli, N, Campanati, A, Campione, E, Carugno, A, Chersi, K, Conti, A, Costanzo, A, Cozzani, E, Cuccia, A, D'Amico, D, Dal Bello, G, Dall'Olio, E, Dapavo, P, De Simone, C, Di Brizzi, E, Di Cesare, A, Dini, V, Esposito, M, Errichetti, E, Fargnoli, M, Fiorella, C, Foti, A, Fratton, Z, Gaiani, F, Gisondi, P, Giuffrida, R, Giunta, A, Guarneri, C, Legori, A, Loconsole, F, Malagoli, P, Narcisi, A, Paolinelli, M, Potestio, L, Prignano, F, Rech, G, Rossi, A, Skroza, N, Trovato, F, Venturini, M, Richetta, A, Pellacani, G, Dattola, A, Brunasso, Amg, Dall'Olio, E G, Di Brizzi, E V, Fargnoli, M C, Fiorella, C S, Gaiani, F M, Richetta, A G, Orsini, D, Megna, M, Assorgi, C, Balato, A, Balestri, R, Bernardini, N, Bettacchi, A, Bianchelli, T, Bianchi, L, Buggiani, G, Burlando, M, Brunasso, A, Caldarola, G, Cameli, N, Campanati, A, Campione, E, Carugno, A, Chersi, K, Conti, A, Costanzo, A, Cozzani, E, Cuccia, A, D'Amico, D, Dal Bello, G, Dall'Olio, E, Dapavo, P, De Simone, C, Di Brizzi, E, Di Cesare, A, Dini, V, Esposito, M, Errichetti, E, Fargnoli, M, Fiorella, C, Foti, A, Fratton, Z, Gaiani, F, Gisondi, P, Giuffrida, R, Giunta, A, Guarneri, C, Legori, A, Loconsole, F, Malagoli, P, Narcisi, A, Paolinelli, M, Potestio, L, Prignano, F, Rech, G, Rossi, A, Skroza, N, Trovato, F, Venturini, M, Richetta, A, Pellacani, G, Dattola, A, Brunasso, Amg, Dall'Olio, E G, Di Brizzi, E V, Fargnoli, M C, Fiorella, C S, Gaiani, F M, and Richetta, A G

Abstract

Purpose of the article: The aim of this multicenter observational study is to report data from real world on the use of bimekizumab in patients aged ≥ 65 years with moderate-to-severe plaque psoriasis. Elderly patients are poorly represented in clinical trials on bimekizumab for plaque psoriasis, and real-world studies are important to guide clinical choices. Materials and methods: A retrospective multicenter study was conducted in 33 dermatological outpatient clinics in Italy. Patients aged ≥ 65 years, with moderate-to-severe plaque psoriasis and treated with bimekizumab were enrolled. No exclusion criteria were applied. Bimekizumab was administered following the Italian Guidelines for the management of plaque psoriasis and according to the summary of product characteristics, in adult patients who were candidates for systemic treatments. Overall, 98 subjects were included, and received bimekizumab up to week 36. Clinical and demographic data were collected before the initiation of treatment with bimekizumab. At baseline and each dermatological examination (4, 16, and 36 weeks), clinical outcomes were measured by the following parameters: (1) PASI score; (2) site-specific (scalp, palmoplantar, genital, nail) Psoriasis Global Assessment (PGA). At each visit, the occurrence of any adverse events (AEs) was recorded, including serious AEs and AEs leading to bimekizumab discontinuation. Results: The mean PASI score was 16.6 ± 9.4 at baseline and significantly decreased to 4.3 ± 5.2 after 4 weeks (p < 0.001), and 1.1 ± 1.7 after 16 week (p < 0.001). This level of improvement was maintained after 36 weeks (p < 0.001). PASI ≤2 was recorded in 36 (36.7%) at week 4, 68% and 69.4% at week 16 and 36, respectively. By week 16, 86/98 (87.8%) patients reached PASI75, 71/98 (72.4%) obtained PASI90, and 52/98 (53.1%) PASI100. Binary logistic regression tests showed a significant association of PASI100 by week 4 with lower PASI at baseline. PASI 100 at 16 or 36 weeks was not

Published
2024

4. Gender influence and bimekizumab treatment in moderate-to-severe psoriasis: a short term real-life multicenter experience

Author

Diotallevi, F, Richiardi, I, Shevchuk, A, Esposito, M, Vagnozzi, E, Concetta Fargnoli, M, Gisondi, P, Bellinato, F, Assorgi, C, Orsini, D, Brianti, P, Raffaele Mercuri, S, Burlando, M, Cozzani, E, Brunasso, G, Caccavale, S, Di Caprio, R, Balato, A, Caldarola, G, De Simone, C, Campione, E, Giunta, A, Calzavara Pinton, P, Venturini, M, Giovanni Carrera, C, Valerio Marzano, A, Carugno, A, Sena, P, Costanzo, A, Narcisi, A, Cusano, F, Dapavo, P, Quaglino, P, Dattola, A, Giovanni Richetta, A, Gaiani, F, Malagoli, P, Megna, M, Potestio, L, Mortato, E, Loconsole, F, Romano, F, Faragalli, A, Gesuita, R, Campanati, A, Diotallevi, Federico, Richiardi, Irene, Shevchuk, Anna, Esposito, Maria, Vagnozzi, Emanuele, Concetta Fargnoli, Maria, Gisondi, Paolo, Bellinato, Francesco, Assorgi, Chiara, Orsini, Diego, Brianti, Pina, Raffaele Mercuri, Santo, Burlando, Martina, Cozzani, Emanuele, Brunasso, Giovanna, Caccavale, Stefano, Di Caprio, Roberta, Balato, Anna, Caldarola, Giacomo, De Simone, Clara, Campione, Elena, Giunta, Alessandro, Calzavara Pinton, Piergiorgio, Venturini, Marina, Giovanni Carrera, Carlo, Valerio Marzano, Angelo, Carugno, Andrea, Sena, Paolo, Costanzo, Antonio, Narcisi, Alessandra, Cusano, Francesco, Dapavo, Paolo, Quaglino, Pietro, Dattola, Annunziata, Giovanni Richetta, Antonio, Gaiani, Francesca, Malagoli, Piergiorgio, Megna, Matteo, Potestio, Luca, Mortato, Edoardo, Loconsole, Francesco, Romano, Francesca, Faragalli, Andrea, Gesuita, Rosaria, Campanati, Anna, Diotallevi, F, Richiardi, I, Shevchuk, A, Esposito, M, Vagnozzi, E, Concetta Fargnoli, M, Gisondi, P, Bellinato, F, Assorgi, C, Orsini, D, Brianti, P, Raffaele Mercuri, S, Burlando, M, Cozzani, E, Brunasso, G, Caccavale, S, Di Caprio, R, Balato, A, Caldarola, G, De Simone, C, Campione, E, Giunta, A, Calzavara Pinton, P, Venturini, M, Giovanni Carrera, C, Valerio Marzano, A, Carugno, A, Sena, P, Costanzo, A, Narcisi, A, Cusano, F, Dapavo, P, Quaglino, P, Dattola, A, Giovanni Richetta, A, Gaiani, F, Malagoli, P, Megna, M, Potestio, L, Mortato, E, Loconsole, F, Romano, F, Faragalli, A, Gesuita, R, Campanati, A, Diotallevi, Federico, Richiardi, Irene, Shevchuk, Anna, Esposito, Maria, Vagnozzi, Emanuele, Concetta Fargnoli, Maria, Gisondi, Paolo, Bellinato, Francesco, Assorgi, Chiara, Orsini, Diego, Brianti, Pina, Raffaele Mercuri, Santo, Burlando, Martina, Cozzani, Emanuele, Brunasso, Giovanna, Caccavale, Stefano, Di Caprio, Roberta, Balato, Anna, Caldarola, Giacomo, De Simone, Clara, Campione, Elena, Giunta, Alessandro, Calzavara Pinton, Piergiorgio, Venturini, Marina, Giovanni Carrera, Carlo, Valerio Marzano, Angelo, Carugno, Andrea, Sena, Paolo, Costanzo, Antonio, Narcisi, Alessandra, Cusano, Francesco, Dapavo, Paolo, Quaglino, Pietro, Dattola, Annunziata, Giovanni Richetta, Antonio, Gaiani, Francesca, Malagoli, Piergiorgio, Megna, Matteo, Potestio, Luca, Mortato, Edoardo, Loconsole, Francesco, Romano, Francesca, Faragalli, Andrea, Gesuita, Rosaria, and Campanati, Anna

Published
2024

5. Effectiveness of ixekizumab for the treatment of moderate‐to‐severe plaque psoriasis with involvement of difficult‐to‐treat areas: A 52‐week multicenter retrospective study

Author

Valenti, M, Gargiulo, L, Ibba, L, Cortese, A, Toso, F, Orsini, D, Lora, V, Frascione, P, Sena, P, Carugno, A, Assorgi, C, Costanzo, A, Narcisi, A, Valenti, Mario, Gargiulo, Luigi, Ibba, Luciano, Cortese, Andrea, Toso, Francesco, Orsini, Diego, Lora, Viviana, Frascione, Pasquale, Sena, Paolo, Carugno, Andrea, Assorgi, Chiara, Costanzo, Antonio, Narcisi, Alessandra, Valenti, M, Gargiulo, L, Ibba, L, Cortese, A, Toso, F, Orsini, D, Lora, V, Frascione, P, Sena, P, Carugno, A, Assorgi, C, Costanzo, A, Narcisi, A, Valenti, Mario, Gargiulo, Luigi, Ibba, Luciano, Cortese, Andrea, Toso, Francesco, Orsini, Diego, Lora, Viviana, Frascione, Pasquale, Sena, Paolo, Carugno, Andrea, Assorgi, Chiara, Costanzo, Antonio, and Narcisi, Alessandra

Abstract

Biological drugs have dramatically changed the approach to treating moderate-to-severe plaque psoriasis, achieving excellent skin clearance and safety outcomes. However, the management of difficult-to-treat areas (e.g., scalp, palms/soles, nails, and genitalia) still represents a challenge in psoriasis treatment. Data in the literature on difficult-to-treat sites are limited and, frequently, no specific analysis is performed during clinical trials. We conducted a 52-week, retrospective study to evaluate the effectiveness of ixekizumab in 120 patients with moderate-to-severe plaque psoriasis of at least one difficult-to-treat area (scalp, palmoplantar surfaces, nails, and genitalia). Ninety-nine patients had scalp psoriasis, 35 had involvement of the palms or soles, 27 were affected by genital psoriasis, and 22 patients reported involvement of the nails. After 1 year of treatment, 96% of patients with scalp involvement, 95.6% of patients with palmoplantar psoriasis, 95.2% of patients with genital psoriasis, and 85% of patients with nail involvement achieved a site-specific Physician's Global Assessment of 0 or 1 (clear or almost clear). No serious adverse events were observed during the study. Our study supports the effectiveness of ixekizumab in plaque psoriasis involving difficult-to-treat sites.

Published
2024

6. Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis)

Author

Orsini, D, Malagoli, P, Balato, A, Bianchi, L, Brianti, P, Buononato, D, Burlando, M, Caldarola, G, Campanati, A, Campione, E, Carrera, C, Carugno, A, Cusano, F, Dapavo, P, Dattola, A, De Simone, C, Dini, V, Esposito, M, Fargnoli, M, Gaiani, F, Gargiulo, L, Gisondi, P, Giunta, A, Ibba, L, Lasagni, C, Loconsole, F, Maione, V, Mortato, E, Marzano, A, Maurelli, M, Megna, M, Mercuri, S, Narcisi, A, Offidani, A, Paolino, G, Parodi, A, Pellacani, G, Potestio, L, Quaglino, P, Richetta, A, Romano, F, Sena, P, Venturini, M, Assorgi, C, Costanzo, A, Orsini, Diego, Malagoli, Piergiorgio, Balato, Anna, Bianchi, Luca, Brianti, Pina, Buononato, Dario, Burlando, Martina, Caldarola, Giacomo, Campanati, Anna, Campione, Elena, Carrera, Carlo G, Carugno, Andrea, Cusano, Francesco, Dapavo, Paolo, Dattola, Annunziata, De Simone, Clara, Dini, Valentina, Esposito, Maria, Fargnoli, Maria C, Gaiani, Francesca M, Gargiulo, Luigi, Gisondi, Paolo, Giunta, Alessandro, Ibba, Luciano, Lasagni, Claudia, Loconsole, Francesco, Maione, Vincenzo, Mortato, Edoardo, Marzano, Angelo V, Maurelli, Martina, Megna, Matteo, Mercuri, Santo R, Narcisi, Alessandra, Offidani, Annamaria, Paolino, Giovanni, Parodi, Aurora, Pellacani, Giovanni, Potestio, Luca, Quaglino, Pietro, Richetta, Antonio G, Romano, Francesca, Sena, Paolo, Venturini, Marina, Assorgi, Chiara, Costanzo, Antonio, Orsini, D, Malagoli, P, Balato, A, Bianchi, L, Brianti, P, Buononato, D, Burlando, M, Caldarola, G, Campanati, A, Campione, E, Carrera, C, Carugno, A, Cusano, F, Dapavo, P, Dattola, A, De Simone, C, Dini, V, Esposito, M, Fargnoli, M, Gaiani, F, Gargiulo, L, Gisondi, P, Giunta, A, Ibba, L, Lasagni, C, Loconsole, F, Maione, V, Mortato, E, Marzano, A, Maurelli, M, Megna, M, Mercuri, S, Narcisi, A, Offidani, A, Paolino, G, Parodi, A, Pellacani, G, Potestio, L, Quaglino, P, Richetta, A, Romano, F, Sena, P, Venturini, M, Assorgi, C, Costanzo, A, Orsini, Diego, Malagoli, Piergiorgio, Balato, Anna, Bianchi, Luca, Brianti, Pina, Buononato, Dario, Burlando, Martina, Caldarola, Giacomo, Campanati, Anna, Campione, Elena, Carrera, Carlo G, Carugno, Andrea, Cusano, Francesco, Dapavo, Paolo, Dattola, Annunziata, De Simone, Clara, Dini, Valentina, Esposito, Maria, Fargnoli, Maria C, Gaiani, Francesca M, Gargiulo, Luigi, Gisondi, Paolo, Giunta, Alessandro, Ibba, Luciano, Lasagni, Claudia, Loconsole, Francesco, Maione, Vincenzo, Mortato, Edoardo, Marzano, Angelo V, Maurelli, Martina, Megna, Matteo, Mercuri, Santo R, Narcisi, Alessandra, Offidani, Annamaria, Paolino, Giovanni, Parodi, Aurora, Pellacani, Giovanni, Potestio, Luca, Quaglino, Pietro, Richetta, Antonio G, Romano, Francesca, Sena, Paolo, Venturini, Marina, Assorgi, Chiara, and Costanzo, Antonio

Abstract

Introduction: Genital involvement is observed in approximately 60% of patients with psoriasis, presenting clinicians with formidable challenges in treatment. While new biologic drugs have emerged as safe and effective options for managing psoriasis, their efficacy in challenging-to-treat areas remains inadequately explored. Intriguingly, studies have shown that interleukin (IL)-17 inhibitors exhibit effectiveness in addressing genital psoriasis. Objectives: We aimed to determine the effectiveness profile of bimekizumab in patients affected by moderate-to-severe plaque psoriasis with involvement of genitalia. Methods: Bimekizumab, a dual inhibitor of both IL-17A and IL-17F, was the focus of our 16-week study, demonstrating highly favorable outcomes for patients with genital psoriasis. The effectiveness of bimekizumab was evaluated in terms of improvement in Static Physician's Global Assessment of Genitalia (sPGA-G) and Psoriasis Area and Severity Index. Results: Sixty-five adult patients were enrolled. Remarkably, 98.4% of our participants achieved a clear sPGA-G score (s-PGA-g=0) within 16 weeks. Moreover, consistent improvements were observed in PASI scores, accompanied by a significant reduction in the mean Dermatology Life Quality Index (DLQI), signifying enhanced quality of life. Notably, none of the patients reported a severe impairment in their quality of life after 16 weeks of treatment. In our cohort of 65 patients, subgroup analyses unveiled that the effectiveness of bimekizumab remained unaffected by prior exposure to other biologics or by obesity. Conclusions: Our initial findings suggest that bimekizumab may serve as a valuable treatment option for genital psoriasis. Nevertheless, further research with larger sample sizes and longer-term follow-up is imperative to conclusively validate these results.

Published
2024

7. Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis)

Author

Gargiulo, L, Ibba, L, Cascio Ingurgio, R, Malagoli, P, Amoruso, F, Balato, A, Bardazzi, F, Brianti, P, Brunasso, G, Burlando, M, Cagni, A, Caproni, M, Carrera, C, Carugno, A, Caudullo, F, Cuccia, A, Dapavo, P, Di Brizzi, E, Dini, V, Gaiani, F, Gisondi, P, Guarneri, C, Lasagni, C, Licata, G, Loconsole, F, Marzano, A, Megna, M, Mercuri, S, Musumeci, M, Orsini, D, Ribero, S, Ruffo Di Calabria, V, Satolli, F, Strippoli, D, Travaglini, M, Trovato, E, Venturini, M, Zichichi, L, Valenti, M, Costanzo, A, Narcisi, A, Gargiulo, Luigi, Ibba, Luciano, Cascio Ingurgio, Ruggero, Malagoli, Piergiorgio, Amoruso, Fabrizio, Balato, Anna, Bardazzi, Federico, Brianti, Pina, Brunasso, Giovanna, Burlando, Martina, Cagni, Anna E, Caproni, Marzia, Carrera, Carlo G, Carugno, Andrea, Caudullo, Francesco, Cuccia, Aldo, Dapavo, Paolo, Di Brizzi, Eugenia V, Dini, Valentina, Gaiani, Francesca M, Gisondi, Paolo, Guarneri, Claudio, Lasagni, Claudia, Licata, Gaetano, Loconsole, Francesco, Marzano, Angelo V, Megna, Matteo, Mercuri, Santo R, Musumeci, Maria L, Orsini, Diego, Ribero, Simone, Ruffo Di Calabria, Valentina, Satolli, Francesca, Strippoli, Davide, Travaglini, Massimo, Trovato, Emanuele, Venturini, Marina, Zichichi, Leonardo, Valenti, Mario, Costanzo, Antonio, Narcisi, Alessandra, Gargiulo, L, Ibba, L, Cascio Ingurgio, R, Malagoli, P, Amoruso, F, Balato, A, Bardazzi, F, Brianti, P, Brunasso, G, Burlando, M, Cagni, A, Caproni, M, Carrera, C, Carugno, A, Caudullo, F, Cuccia, A, Dapavo, P, Di Brizzi, E, Dini, V, Gaiani, F, Gisondi, P, Guarneri, C, Lasagni, C, Licata, G, Loconsole, F, Marzano, A, Megna, M, Mercuri, S, Musumeci, M, Orsini, D, Ribero, S, Ruffo Di Calabria, V, Satolli, F, Strippoli, D, Travaglini, M, Trovato, E, Venturini, M, Zichichi, L, Valenti, M, Costanzo, A, Narcisi, A, Gargiulo, Luigi, Ibba, Luciano, Cascio Ingurgio, Ruggero, Malagoli, Piergiorgio, Amoruso, Fabrizio, Balato, Anna, Bardazzi, Federico, Brianti, Pina, Brunasso, Giovanna, Burlando, Martina, Cagni, Anna E, Caproni, Marzia, Carrera, Carlo G, Carugno, Andrea, Caudullo, Francesco, Cuccia, Aldo, Dapavo, Paolo, Di Brizzi, Eugenia V, Dini, Valentina, Gaiani, Francesca M, Gisondi, Paolo, Guarneri, Claudio, Lasagni, Claudia, Licata, Gaetano, Loconsole, Francesco, Marzano, Angelo V, Megna, Matteo, Mercuri, Santo R, Musumeci, Maria L, Orsini, Diego, Ribero, Simone, Ruffo Di Calabria, Valentina, Satolli, Francesca, Strippoli, Davide, Travaglini, Massimo, Trovato, Emanuele, Venturini, Marina, Zichichi, Leonardo, Valenti, Mario, Costanzo, Antonio, and Narcisi, Alessandra

Abstract

Purpose: Tildrakizumab is a selective inhibitor of IL-23 approved for the treatment of moderate-to-severe plaque psoriasis in two dosages. We conducted a 16-week multicenter retrospective study to compare the effectiveness and safety of tildrakizumab 200 mg versus tildrakizumab 100 mg in patients with a high disease burden or high body weight. Materials and methods: Our retrospective study included 134 patients treated with tildrakizumab 200 mg and 364 patients treated with tildrakizumab 100 mg from 28 Italian Dermatology Units affected by moderate-to-severe plaque psoriasis. The patients had a body weight above 90 kg or a high disease burden (Psoriasis Area and Severity Index [PASI] ≥ 16 or the involvement of difficult-to-treat areas). We evaluated the effectiveness of tildrakizumab at the week-16 visit in terms of PASI90, PASI100 and absolute PASI ≤ 2. Results: After 16 weeks of treatment with tildrakizumab 200 mg, PASI90 was reached by 57.5% of patients and PASI100 by 39.6% of patients. At the same time point, 34.3% and 24.2% of patients treated with tildrakizumab 100 mg achieved PASI90 and PASI100, respectively. Conclusions: Our data suggest that tildrakizumab 200 mg has better effectiveness than tildrakizumab 100 mg in patients with a body weight ≥ 90 kg and a high disease burden.

Published
2024

8. Profilo super responder in corso di trattamento con bimekizumab: studio retrospettivo multicentrico nella psoriasi moderato-grave

Author

Esposito, M, Vagnozzi, E, Di Caprio, R, Assorgi, C, Bellinato, F, Brianti, P, Burlando, M, Brunasso, G, Caccavale, S, Caldarola, G, Campione, E, Calzavara-Pinton, P, Campanati, A, Carrera, C, Carugno, A, Cozzani, E, Costanzo, A, Cusano, F, Dapavo, P, Dattola, A, De Simone, C, Diotallevi, F, Fargnoli, M, Gaiani, F, Giunta, A, Malagoli, P, Marzano, A, Megna, M, Mercuri, S, Mortato, E, Narcisi, A, Orsini, D, Potestio, L, Quaglino, P, Richetta, A, Romano, F, Sena, P, Venturini, M, Loconsole, F, Gisondi, P, Balato, A, Carrera, CG, Fargnoli, MC, Marzano, AV, Mercuri, SR, Richetta, AG, Esposito, M, Vagnozzi, E, Di Caprio, R, Assorgi, C, Bellinato, F, Brianti, P, Burlando, M, Brunasso, G, Caccavale, S, Caldarola, G, Campione, E, Calzavara-Pinton, P, Campanati, A, Carrera, C, Carugno, A, Cozzani, E, Costanzo, A, Cusano, F, Dapavo, P, Dattola, A, De Simone, C, Diotallevi, F, Fargnoli, M, Gaiani, F, Giunta, A, Malagoli, P, Marzano, A, Megna, M, Mercuri, S, Mortato, E, Narcisi, A, Orsini, D, Potestio, L, Quaglino, P, Richetta, A, Romano, F, Sena, P, Venturini, M, Loconsole, F, Gisondi, P, Balato, A, Carrera, CG, Fargnoli, MC, Marzano, AV, Mercuri, SR, and Richetta, AG

Abstract

Bimekizumab è un anticorpo monoclonale umanizzato, recentemente approvato per il trattamento della psoriasi a placche moderato-grave, inibitore selettivo delle isoforme dell’interleuchina-17A e F. Le esperienze real-life riguardanti l’utilizzo del farmaco sono limitate ed il profilo del paziente con riposta più elevata PASI100 cioè super responder SR non è stato analizzato. Presentiamo questo studio multicentrico, retrospettivo volto a disegnare il profilo del paziente che beneficia maggiormente del trattamento con bimekizumab, considerando come SR coloro che raggiungono PASI 100 alla settimana-4 e 16. Sono stati studiati pazienti adulti affetti da psoriasi moderato-grave, trattati con bimekizumab per almeno 16 settimane presso 21 centri dermatologici italiani, secondo regole di appropriatezza AIFA e in accordo con la scheda tecnica del farmaco. Endpoints di efficacia erano PASI75, PASI90 e PASI100 alla settimana 4 e 16, ed in particolare la percentuale di SR ai due tempi. I pazienti che non raggiungevano tale target venivano definiti come non-super responders NSRs. Sono stati studiati 137 pazienti con età media 52,47±15,56 anni, BMI medio 27,43±5,91 e PASI medio al basale di 16,00±9,29. Alla settimana 4 il 72% dei pazienti raggiungeva PASI75, il 50% PASI90, mentre il 43% otteneva PASI100, definendo la popolazione SR alla settimana 4. Alla settimana 16, il 93% dei pazienti raggiungeva PASI75, il 77% PASI90, il 70% dei pazienti risultava essere SR mentre solo il 7% non raggiungeva PASI 75. Sono emerse alcune differenze caratterizzanti pazienti con un più rapido raggiungimento dello stato di SRs alla settimana 4 rispetto alla settimana 16: età ≥46<65, coesistenza di <2 comorbidità e stato naïve a precedenti trattamenti biologici. Considerando alcune caratteristiche clinico-demografiche è stata condotta un’analisi univariata per valutare le differenze tra SR e NSRs. Lo stato di NSR è risultato associato significativamente alla settimana 4 con: BMI≥25 &

Published
2024

11. A risankizumab super responder profile identified by long‐term real‐life observation‐IL PSO (ITALIAN LANDSCAPE PSORIASIS)

Author

Gargiulo, L., primary, Ibba, L., additional, Malagoli, P., additional, Amoruso, F., additional, Argenziano, G., additional, Balato, A., additional, Bardazzi, F., additional, Burlando, M., additional, Carrera, C. G., additional, Damiani, G., additional, Dapavo, P., additional, Dini, V., additional, Fabbrocini, G., additional, Franchi, C., additional, Gaiani, F. M., additional, Girolomoni, G., additional, Guarneri, C., additional, Lasagni, C., additional, Loconsole, F., additional, Marzano, A. V., additional, Maurelli, M., additional, Megna, M., additional, Orsini, D., additional, Sampogna, F., additional, Travaglini, M., additional, Valenti, M., additional, Costanzo, A., additional, and Narcisi, A., additional

Published
2023
Full Text
View/download PDF

12. Effectiveness and safety of anti‐IL‐23 and anti‐IL‐17 biological therapies for psoriasis in elderly patients: Real‐world experience from two Italian hospitals

Author

Fiorillo, G., primary, Ibba, L., additional, Gargiulo, L., additional, Vignoli, C. A., additional, Alfano, A., additional, Cortese, A., additional, Toso, F., additional, Orsini, D., additional, Iacovelli, P., additional, Frascione, P., additional, Narcisi, A., additional, Costanzo, A., additional, and Valenti, M., additional

Published
2023
Full Text
View/download PDF

14. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)

Author

Gargiulo, L, Narcisi, A, Ibba, L, Balato, A, Bianchi, L, Brianti, P, Buononato, D, Burlando, M, Caldarola, G, Campanati, A, Campione, E, Carrera, C, Carugno, A, Cristaudo, A, Cusano, F, Dapavo, P, Dattola, A, De Simone, C, Gaiani, F, Gisondi, P, Giunta, A, Loconsole, F, Maione, V, Mortato, E, Marzano, A, Maurelli, M, Megna, M, Mercuri, S, Offidani, A, Orsini, D, Parodi, A, Pellacani, G, Potestio, L, Quaglino, P, Richetta, A, Romano, F, Sena, P, Venturini, M, Malagoli, P, Costanzo, A, Gargiulo, Luigi, Narcisi, Alessandra, Ibba, Luciano, Balato, Anna, Bianchi, Luca, Brianti, Pina, Buononato, Dario, Burlando, Martina, Caldarola, Giacomo, Campanati, Anna, Campione, Elena, Carrera, Carlo G., Carugno, Andrea, Cristaudo, Antonio, Cusano, Francesco, Dapavo, Paolo, Dattola, Annunziata, De Simone, Clara, Gaiani, Francesca M., Gisondi, Paolo, Giunta, Alessandro, Loconsole, Francesco, Maione, Vincenzo, Mortato, Edoardo, Marzano, Angelo V., Maurelli, Martina, Megna, Matteo, Mercuri, Santo R., Offidani, Annamaria, Orsini, Diego, Parodi, Aurora, Pellacani, Giovanni, Potestio, Luca, Quaglino, Pietro, Richetta, Antonio G., Romano, Francesca, Sena, Paolo, Venturini, Marina, Malagoli, Piergiorgio, Costanzo, Antonio, Gargiulo, L, Narcisi, A, Ibba, L, Balato, A, Bianchi, L, Brianti, P, Buononato, D, Burlando, M, Caldarola, G, Campanati, A, Campione, E, Carrera, C, Carugno, A, Cristaudo, A, Cusano, F, Dapavo, P, Dattola, A, De Simone, C, Gaiani, F, Gisondi, P, Giunta, A, Loconsole, F, Maione, V, Mortato, E, Marzano, A, Maurelli, M, Megna, M, Mercuri, S, Offidani, A, Orsini, D, Parodi, A, Pellacani, G, Potestio, L, Quaglino, P, Richetta, A, Romano, F, Sena, P, Venturini, M, Malagoli, P, Costanzo, A, Gargiulo, Luigi, Narcisi, Alessandra, Ibba, Luciano, Balato, Anna, Bianchi, Luca, Brianti, Pina, Buononato, Dario, Burlando, Martina, Caldarola, Giacomo, Campanati, Anna, Campione, Elena, Carrera, Carlo G., Carugno, Andrea, Cristaudo, Antonio, Cusano, Francesco, Dapavo, Paolo, Dattola, Annunziata, De Simone, Clara, Gaiani, Francesca M., Gisondi, Paolo, Giunta, Alessandro, Loconsole, Francesco, Maione, Vincenzo, Mortato, Edoardo, Marzano, Angelo V., Maurelli, Martina, Megna, Matteo, Mercuri, Santo R., Offidani, Annamaria, Orsini, Diego, Parodi, Aurora, Pellacani, Giovanni, Potestio, Luca, Quaglino, Pietro, Richetta, Antonio G., Romano, Francesca, Sena, Paolo, Venturini, Marina, Malagoli, Piergiorgio, and Costanzo, Antonio

Abstract

Introduction: Bimekizumab is a monoclonal antibody that targets Interleukin-17 A and F, approved for the treatment of moderate-to-severe plaque psoriasis. While bimekizumab has been evaluated in several phase-III clinical trials, real-world evidence is still very limited. Method: This multicenter retrospective study included patients affected by plaque psoriasis treated with bimekizumab from May 1, 2022 to April 30, 2023, at 19 Italian referral hospitals. Patients affected by moderate-to-severe plaque psoriasis eligible for systemic treatments were included. The effectiveness of bimekizumab was evaluated in terms of reduction in psoriasis area and severity index (PASI) compared with baseline at weeks 4 and 16. The main outcomes were the percentages of patients achieving an improvement of at least 75% (PASI75), 90% (PASI90) and 100% (PASI100) in PASI score. Results: The study included 237 patients who received at least one injection of bimekizumab. One hundred and seventy-one patients and 114 reached four and 16 weeks of follow-up, respectively. Complete skin clearance was achieved by 43.3% and 75.4% of patients at weeks 4 and 16, respectively. At week 16, 86.8% of patients reported no impact on their quality of life. At week 16, there were no significant differences between bio-naïve and bio-experienced patients in terms of PASI75, PASI90 and PASI100. The most commonly reported adverse events (AEs) were oral candidiasis (10.1%). No severe AEs or AEs leading to discontinuation were observed throughout the study. Conclusion: Our experience supports the effectiveness and tolerability of bimekizumab in a real-world setting with similar results compared with phase-III clinical trials.

Published
2023

15. Stroke pathway performance assessment: a retrospective observational study

Author

Camporesi, J, Strumia, S, Di Pilla, Andrea, Paolucci, M, Orsini, Diego, Assorgi, C, Cacciuttolo, Maria Gabriella, Specchia, Maria Lucia, Di Pilla A, Orsini D, Cacciuttolo MG, Specchia ML (ORCID:0000-0002-3859-4591), Camporesi, J, Strumia, S, Di Pilla, Andrea, Paolucci, M, Orsini, Diego, Assorgi, C, Cacciuttolo, Maria Gabriella, Specchia, Maria Lucia, Di Pilla A, Orsini D, Cacciuttolo MG, and Specchia ML (ORCID:0000-0002-3859-4591)

Abstract

Background and Aim: Performance assessment of the Stroke Pathway is a key element in healthcare quality. The aim of this study has been to carry out a retrospective assessment of the Stroke Pathway in a first level Stroke Unit in Italy, analyzing the temporal trend of the Stroke Pathway performance and the impact of the COVID-19 pandemic. Methods: A retrospective observational study was carried out analyzing data from 1/01/2010 to 31/12/2020. The following parameters were considered: volume and characteristics of patients with ischemic stroke undergoing intravenous thrombolysis, baseline modified Rankin Scale (mRS) and National Institutes of Health Stroke Scale (NIHSS) scores, Onset-to-Door (OTD), Door-To-Imaging (DTI) and Door-To-Needle (DTN) Times, mRS score 3 months after the ischemic event onset (3 m-mRS) and NIHSS score 24 h after the ischemic event onset (24 h-NIHSS). The study also compared the pre-COVID-19 pandemic period (March-December 2019) with the one immediately following it (March-December 2020). Results: 418 patients were included. Over time, treatment was extended to older patients (mean age from 66.3 to 75.51 years; p = 0.006) and with a higher level of baseline disability (baseline mRS score from 0.22 to 1.22; p = 0.000). A statistically significant reduction over the years was found for DTN, going from 90 min to 61 min (p = 0.000) with also an increase in the number of thrombolysis performed within the “golden hour” – more than 50% in 2019 and more of 60% in 2020. Comparing pre- and during COVID-19 pandemic periods, the number of patients remained almost unchanged, but with a significantly higher baseline disability (mRS = 1.18 vs. 0.72, p = 0.048). The pre-hospital process indicator OTD increased from 88.13 to 118.48 min, although without a statistically significant difference (p = 0.197). Despite the difficulties for hospitals due to pandemic, the hospital process indicators DTI and DTN remained substantially unchanged, as well as the clinical

Published
2023

16. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)

Author

Gargiulo, L., Narcisi, A., Ibba, L., Balato, A., Bianchi, L., Brianti, P., Buononato, D., Burlando, M., Caldarola, Giacomo, Campanati, A., Campione, E., Carrera, C. G., Carugno, A., Cristaudo, A., Cusano, F., Dapavo, P., Dattola, Carmelo Alberto, De Simone, Clara, Gaiani, F. M., Gisondi, P., Giunta, A., Loconsole, F., Maione, V., Mortato, E., Marzano, A. V., Maurelli, M., Megna, M., Mercuri, S. R., Offidani, A., Orsini, Diego, Parodi, A., Pellacani, G., Potestio, L., Quaglino, P., Richetta, A. G., Romano, Federica, Sena, P., Venturini, M., Malagoli, P., Costanzo, Rosa Maria Alba, Caldarola G. (ORCID:0000-0002-8837-9232), Dattola A., De Simone C. (ORCID:0000-0002-0898-0045), Orsini D., Romano F., Costanzo A., Gargiulo, L., Narcisi, A., Ibba, L., Balato, A., Bianchi, L., Brianti, P., Buononato, D., Burlando, M., Caldarola, Giacomo, Campanati, A., Campione, E., Carrera, C. G., Carugno, A., Cristaudo, A., Cusano, F., Dapavo, P., Dattola, Carmelo Alberto, De Simone, Clara, Gaiani, F. M., Gisondi, P., Giunta, A., Loconsole, F., Maione, V., Mortato, E., Marzano, A. V., Maurelli, M., Megna, M., Mercuri, S. R., Offidani, A., Orsini, Diego, Parodi, A., Pellacani, G., Potestio, L., Quaglino, P., Richetta, A. G., Romano, Federica, Sena, P., Venturini, M., Malagoli, P., Costanzo, Rosa Maria Alba, Caldarola G. (ORCID:0000-0002-8837-9232), Dattola A., De Simone C. (ORCID:0000-0002-0898-0045), Orsini D., Romano F., and Costanzo A.

Abstract

Introduction: Bimekizumab is a monoclonal antibody that targets Interleukin-17 A and F, approved for the treatment of moderate-to-severe plaque psoriasis. While bimekizumab has been evaluated in several phase-III clinical trials, real-world evidence is still very limited. Method: This multicenter retrospective study included patients affected by plaque psoriasis treated with bimekizumab from May 1, 2022 to April 30, 2023, at 19 Italian referral hospitals. Patients affected by moderate-to-severe plaque psoriasis eligible for systemic treatments were included. The effectiveness of bimekizumab was evaluated in terms of reduction in psoriasis area and severity index (PASI) compared with baseline at weeks 4 and 16. The main outcomes were the percentages of patients achieving an improvement of at least 75% (PASI75), 90% (PASI90) and 100% (PASI100) in PASI score. Results: The study included 237 patients who received at least one injection of bimekizumab. One hundred and seventy-one patients and 114 reached four and 16 weeks of follow-up, respectively. Complete skin clearance was achieved by 43.3% and 75.4% of patients at weeks 4 and 16, respectively. At week 16, 86.8% of patients reported no impact on their quality of life. At week 16, there were no significant differences between bio-naïve and bio-experienced patients in terms of PASI75, PASI90 and PASI100. The most commonly reported adverse events (AEs) were oral candidiasis (10.1%). No severe AEs or AEs leading to discontinuation were observed throughout the study. Conclusion: Our experience supports the effectiveness and tolerability of bimekizumab in a real-world setting with similar results compared with phase-III clinical trials.

Published
2023

17. Risankizumab for the treatment of genital psoriasis: A 1‐year, real‐world experience.

Author

Orsini, D., Frascione, P., Assorgi, C., Pacifico, A., Sperduti, I., Gargiulo, L., Ibba, L., Valenti, M., Costanzo, A., and Narcisi, A.

Subjects
*PSORIASIS, *PSORIATIC arthritis
Abstract

This article discusses a study on the use of risankizumab for the treatment of genital psoriasis. Genital involvement in psoriasis can have a significant impact on quality of life and sexual activity. The study found that risankizumab, a monoclonal antibody that blocks interleukin-23, was effective in reducing psoriasis symptoms in the genital area. The treatment showed a fast onset of action and sustained effectiveness for up to 52 weeks. The study also reported a favorable safety profile, with no relevant adverse events or treatment discontinuation due to side effects. However, further research is needed to evaluate long-term management of genital psoriasis. [Extracted from the article]

Published
2024
Full Text
View/download PDF

18. The educational value, both past and present, of an ancient scientific collection: the collection of anatomical preparations illustrating the various phases of bone development, from the second month of intrauterine life to adulthood

Author

Martini, M., Aglianò, M., and Orsini, D.

Subjects
Italy, anatomical preparations, ancient scientific collection, educational value, ethics, medical education, Museum of Siena
Abstract

Italy’s museums possess an enormous patrimony of historical scientific artefacts. This raises important questions regarding the conservation and safeguard of such materials and prompts reflection as to the utility of current modalities of popularising science. The collections housed in scientific museums were created in order to promote scientific education by making science more accessible and more comprehensible. The authors ask whether this heritage can still be used for educational purposes today, and examine a collection of preparations on the ossification of human bones in the Anatomical Museum of the University of Siena. They conclude that such materials can still be of educational value if they are made part of exhibitions that meet the needs of the public and of students in training. Indeed, it is essential to bear witness to the long pathway of the development of scientific knowledge and, in particular, to the value of the research on which this knowledge is based. Through the implementation of ad hoc exhibitions, this precious historical scientific patrimony can continue to play an important role in presenting medical/healthcare issues of topical interest without losing sight of the relevance of past experience to basic teaching.

Published
2022

26. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis. results from extension phase of the SUPREME study

Author

Papini, M, Cusano, F, Romanelli, M, Burlando, M, Stinco, G, Girolomoni, G, Peris, K, Potenza, C, Offidani, A, Bartezaghi, M, Aloisi, E, Costanzo A, Bianchi L, Bottoni U, Buligan C, Brazzelli V, Campanati A, Cantoresi F, Capo A, Cattaneo A, Dapavo P, Del Giglio M, Di Lernia V, Di Nuzzo S, De Simone C, Dusi D, Fargnoli MC, Flori ML, Franchi C, Galluzzo M, Ghilardi A, Hansel K, Loconsole F, Lora V, Malagoli P, Malara G, Mastrandrea V, Megna M, Mercuri SR, Musumeci ML, Naldi L, Narcisi A, Orsini D, Pagnanelli G, Patrizi A, Pau M, Pellacani G, Persechino S, Piaserico S, Pietroleonardo L, Prignano F, Reseghetti A, Russo F, Sirna R, Skroza N, Stingeni L, Trevisini S, Zane C, Zichichi L, Zini A., Papini, M, Cusano, F, Romanelli, M, Burlando, M, Stinco, G, Girolomoni, G, Peris, K, Potenza, C, Offidani, A, Bartezaghi, M, Aloisi, E, Costanzo, A, Bianchi, L, Bottoni, U, Buligan, C, Brazzelli, V, Campanati, A, Cantoresi, F, Capo, A, Cattaneo, A, Dapavo, P, Del Giglio, M, Di Lernia, V, Di Nuzzo, S, De Simone, C, Dusi, D, Fargnoli, Mc, Flori, Ml, Franchi, C, Galluzzo, M, Ghilardi, A, Hansel, K, Loconsole, F, Lora, V, Malagoli, P, Malara, G, Mastrandrea, V, Megna, M, Mercuri, Sr, Musumeci, Ml, Naldi, L, Narcisi, A, Orsini, D, Pagnanelli, G, Patrizi, A, Pau, M, Pellacani, G, Persechino, S, Piaserico, S, Pietroleonardo, L, Prignano, F, Reseghetti, A, Russo, F, Sirna, R, Skroza, N, Stingeni, L, Trevisini, S, Zane, C, Zichichi, L, and Zini, A.

Subjects
Moderate to severe, medicine.medical_specialty, business.industry, secukinumab, HLA-Cw6, Dermatology, Plaque type psoriasis, moderate-to-severe plaque-type psoriasis, Clinical trial, Severity of illness, Monoclonal, Medicine, In patient, Secukinumab, Settore MED/35 - MALATTIE CUTANEE E VENEREE, business, Prospective cohort study
Abstract

Recent studies have shown that biological drugs approved for treating psoriasis and psoriatic arthritis are not effective in all patients, and that variations in the genome have been associated with different clinical responses or side effects. HLA-Cw6 gene is associated with more severe and early-onset psoriasis. Recent reports have shown that HLA-Cw6 status predicts efficacy of some biologic treatments in psoriasis patients. The Phase 3b SUPREME study (NCT02394561) demonstrated the efficacy of secukinumab in patients with moderate-to-severe plaque-type psoriasis, irrespective of HLA-Cw6 status at week 24. This article is protected by copyright. All rights reserved.

Published
2019

30. Tuberculosis in Siena: evolution of the disease and its treatment, from the Unification of Italy to the 1930s

Author

Orsini, D

Subjects
Achille Sclavo, Urbanization, History, 19th Century, Carlo Livi, History of tuberculosis, Prophylaxis activities, Public health, Tuberculosis, History, 20th Century, Ventilation, Crowding, Hospitals, Chronic Disease, Italy, Poverty Areas, Housing, Humans, Public Health, Cities, Sanitation, Tuberculosis, Pulmonary, Research Article
Abstract

Between the end of the nineteenth century and the first half of the twentieth century, the city of Siena experienced elevated tuberculosis-related morbidity and mortality, to the point that on January 1, 1929 the newspaper La Nazione wrote that “Siena ranks second in the official TB incidence rate”. The author presents statistical data relating to a time span ranging from 1898 to 1935, interpreting them in light of social and sanitary conditions found in the city. The result is an exhaustive picture of the most important actions implemented at city level to prevent tuberculosis and to assist and treat the sick, such as: the creation of seaside hospices conceived by Carlo Livi for children suffering from scrofula, as well as centers committed to the prevention of childhood poverty and malnutrition; the realization of activities in the green areas of the ramparts of the Fortress, upon recommendation by great hygienist Achille Sclavo; the establishment of a Preventorium on the premises of the Monastery of Santa Maria Maddalena to accommodate children from families that included pulmonary tuberculosis patients, and countless activities carried out by the Anti-TB Dispensary. Of particular interest is the identification of the main cause of high TB incidence in the unsanitary homes located in some sections of Siena’s district, which, in 1930 engendered a lively debate hinging upon the notion of building restoration., Journal of Preventive Medicine and Hygiene, Vol. 61 No. 1s1 (2020): Tuberculosis. The Never Ending Story: past, present and Future Challeng (Parte I)

Published
2019

31. Physician–patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy

Author

Neri, L., Peris, K., Longo, C., Calvieri, S., Frascione, P., Parodi, A., Eibenschuz, L., Bottoni, U., Pellacani, G., Ayala, F., Quaglino, P., Cannavo, S., Rubegni, P., Ferreli, C., Girolomoni, G., Bongiorno, M. R., Potenza, C., Micali, G., Pimpinelli, N., Romanelli, M., Stanganelli, I., Bonamonte, D., Peserico, A., Fargnoli, M. C., Pinton, P. C., Costanzo, D., Cantisani, C., Borsari, S., Ricci, F., Izzi, S., Chiara, F., Cozzani, E., Carboni, A., Amoruso, G. F., Dastoli, S., Scalvenzi, M., Deboli, T., Francesco, B., Casari, A., Nami, N., Camilla Delle Vedove, C. S., Viola, L., La Carrubba, F., Grandi, V., Dini, V., Mazzoni, L., Vestita, M. L., Fabiano, A., Zane, C., Orsini, D., Neri, L., Peris, K., Longo, C., Calvieri, S., Frascione, P., Parodi, A., Eibenschuz, L., Bottoni, U., Pellacani, G., Ayala, Fabio, Quaglino, Pietro, Cannavò, Serafinella, Rubegni, Pietro, Ferreli, Caterina, Girolomoni, Gianpiero, Bongiorno, Maria Rita, Potenza, Concetta, Micali, Giuseppe, Pimpinelli, Nicola, Romanelli, Marco, Stanganelli, Ignazio, Bonamonte, Domenico, Peserico, Andrea, Fargnoli, Maria Concetta, Pinton, Piergiacomo Calzavara, Costanzo, Domenico, Cantisani, Carmen, Borsari, Stefania, Ricci, Francesco, Izzi, Sara, Chiara, Franceschini, Cozzani, Emanuele, Carboni, Anna, Amoruso, Giuseppe F., Dastoli, Stefano, Scalvenzi, Massimiliano, Deboli, Tommaso, Francesco, Borgia, Casari, Alice, Nami, Nicolò, Camilla Delle Vedove, Chiara Sabbatini, Viola, La, La Carrubba, Francesco, Grandi, Vieri, Dini, Valentina, Mazzoni, Laura, Vestita, Michelangelo la, Fabiano, Antonella, Zane, Cristina, and Orsini, Diego

Subjects
Male, infectious diseases, actinic keratoses, Diclofenac, Actinic, topical field‐directed therapy, Anti-Inflammatory Agents, Antineoplastic Agents, Administration, Cutaneous, Medication Adherence, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal, Diterpenes, Drug Eruptions, Female, Humans, Imiquimod, Italy, Keratosis, Actinic, Longitudinal Studies, Middle Aged, Patient Reported Outcome Measures, Prospective Studies, Quality of Life, Communication, Patient Satisfaction, Physician-Patient Relations, Infectious Diseases, 80 and over, actinic keratose, treatment, Keratosis, Cutaneous, Administration, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Non-Steroidal
Abstract

Background: Patients with multiple actinic keratoses (AKs) should be treated with field-directed therapy. Such treatments challenge patients’ adherence due to out-of-pocket costs, length of treatment and severity of local skin reactions (LSRs). Effective physician–patient communication (PPC) may buffer therapy-related distress, thus improving quality of life, treatment satisfaction and adherence. Objectives: We evaluated the interplay between PPC, LSR intensity (safety) and lesion clearance rates (effectiveness) on treatment satisfaction, quality of life and treatment adherence among patients with multiple AKs receiving topical field-directed therapies. Methods: In this observational, multicentre, longitudinal, cohort study, we included 1136 adult patients with discrete, clinically detectable, visible, multiple (three or more lesions in a 25cm2 area), Grade I/II AKs, for whom the attending dermatologist has prescribed treatment with a topical field-directed therapy. We matched self-reported data and medical information recorded by dermatologists in standard clinical forms. Patients were followed up at two time points (T1: 8days; T2: 25–30days). Results: Most patients were elderly, married, men with poor socio-economic status and multiple lesions of the scalp or face. The majority (n=961) had a prescription of ingenol mebutate (IMB) and 175 received either diclofenac 3% in hyaluronic acid (DHA) or imiquimod 5% (IMQ). Clearance rate at 1month was 84%. Most patients felt very supported (n=819, 73%) and rated dermatologist's explanations very clear (n=608, 54%). Treatment satisfaction (effectiveness and convenience scales) increased along the follow-up, especially for those on IMB (Δpre-post=−4.00; other: Δpre-post=−0.25; interaction P&nbsp

Published
2019

32. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study

Author

Papini, M., Cusano, F., Romanelli, Margherita, Burlando, M., Stinco, G., Girolomoni, G., Peris, Ketty, Potenza, C., Offidani, A., Bartezaghi, M., Aloisi, E., Costanzo, Rosa Maria Alba, Bianchi, L., Bottoni, U., Buligan, C., Brazzelli, V., Campanati, A., Cantoresi, F., Capo, A., Cattaneo, A., Dapavo, P., Giglio, M., Lernia, V., Nuzzo, S., Simone, Carmen, Dusi, D., Fargnoli, Maria Concetta, Flori, L., Franchi, C., Galluzzo, M., Ghilardi, A., Hansel, K., Loconsole, F., Lora, V., Malagoli, P., Malara, G., Mastrandrea, V., Megna, M., Mercuri, R., Musumeci, L., Naldi, L., Narcisi, A., Orsini, Diego, Pagnanelli, G., Patrizi, A., Pau, M., Pellacani, G., Persechino, S., Piaserico, S., Pietroleonardo, L., Prignano, F., Reseghetti, A., Russo, F., Sirna, R., Skroza, N., Stingeni, L., Trevisini, S., Zane, C., Zichichi, L., Zini, A., Romanelli M., Peris K. (ORCID:0000-0002-5237-0463), Costanzo A., Simone C., Fargnoli C., Orsini D., Papini, M., Cusano, F., Romanelli, Margherita, Burlando, M., Stinco, G., Girolomoni, G., Peris, Ketty, Potenza, C., Offidani, A., Bartezaghi, M., Aloisi, E., Costanzo, Rosa Maria Alba, Bianchi, L., Bottoni, U., Buligan, C., Brazzelli, V., Campanati, A., Cantoresi, F., Capo, A., Cattaneo, A., Dapavo, P., Giglio, M., Lernia, V., Nuzzo, S., Simone, Carmen, Dusi, D., Fargnoli, Maria Concetta, Flori, L., Franchi, C., Galluzzo, M., Ghilardi, A., Hansel, K., Loconsole, F., Lora, V., Malagoli, P., Malara, G., Mastrandrea, V., Megna, M., Mercuri, R., Musumeci, L., Naldi, L., Narcisi, A., Orsini, Diego, Pagnanelli, G., Patrizi, A., Pau, M., Pellacani, G., Persechino, S., Piaserico, S., Pietroleonardo, L., Prignano, F., Reseghetti, A., Russo, F., Sirna, R., Skroza, N., Stingeni, L., Trevisini, S., Zane, C., Zichichi, L., Zini, A., Romanelli M., Peris K. (ORCID:0000-0002-5237-0463), Costanzo A., Simone C., Fargnoli C., and Orsini D.

Abstract

na

Published
2019

33. Characteristics and Influence of Biosmoke on the Fine-Particle Ionic Composition Measured in Asian Outflow during the Transport and Chemical Evolution Over the Pacific (TRACE-P) Experiment

Author

Ma, Y, Weber, R. J, Lee, Y.-N, Orsini, D. A, Maxwell-Meier, K, Thornton, D. C, Bandy, A. R, Clarke, A. D, Blake, D. R, and Sachse, G. W

Subjects
Environment Pollution
Abstract

We investigate the sources, prevalence, and fine-particle inorganic composition of biosmoke over the western Pacific Ocean between 24 February and 10 April 2001. The analysis is based on highly time-resolved airborne measurements of gaseous and fine- particle inorganic chemical composition made during the NASA Transport and Chemical Evolution over the Pacific (TRACE-P) experiment. At latitudes below approximately 25 deg. N, relatively pure biomass burning plumes of enhanced fine-particle potassium, nitrate, ammonium, light-absorbing aerosols, and CO concentrations were observed in plumes that back trajectories and satellite fire map data suggest originated from biomass burning in southeast Asia. Fine-particle water-soluble potassium (K+) is confirmed to be a unique biosmoke tracer, and its prevalence throughout the experiment indicates that approximately 20% of the TRACE-P Asian outflow plumes were influenced, to some extent, by biomass or biofuel burning emissions. At latitudes above 25 deg. N, highly mixed urban/industrial and biosmoke plumes, indicated by SO(sup 2, sub 4) and K+, were observed in 5 out of 53 plumes. Most plumes were found in the Yellow Sea and generally were associated with much higher fine-particle loadings than plumes lacking a biosmoke influence. The air mass back trajectories of these mixed plumes generally pass through the latitude range of between 34 deg. and 40 deg. N on the eastern China coast, a region that includes the large urban centers of Beijing and Tianjin. A lack of biomass burning emissions based on fire maps and high correlations between K+ and pollution tracers (e.g., S(sup 2, sub 4) suggest biofuel sources. Ratios of fine-particle potassium to sulfate are used to provide an estimate of relative contributions of biosmoke emissions to the mixed Asian plumes. The ratio is highly correlated with fine-particle volume (r(sup 2) = 0.85) and predicts that for the most polluted plume encounter in TRACE-P, approximately 60% of the plume is associated with biosmoke emissions. On average, biosmoke contributes approximately 35-40% to the measured fine inorganic aerosol mass in the mixed TRACE-P plumes intercepted north of 25% latitude.

Published
2003
Full Text
View/download PDF

34. Intercomparisons of Airborne Measurements of Aerosol Ionic Chemical Composition during TRACE-P and ACE-Asia

Author

Ma, Y, Weber, R. J, Maxwell-Meier, K, Orsini, D. A, Lee, Y.-N, Huebert, B. J, Howell, S. G, Bertram, T, and Talbot, R. W

Subjects
Chemistry And Materials (General)
Abstract

As part of the two field studies, Transport and Chemical Evolution over the Pacific (TRACE-P), and the Asian Aerosol Characterization Experiment (ACEAsia), the inorganic chemical composition of tropospheric aerosols was measured over the western Pacific from three separate aircraft using various methods. Comparisons are made between the rapid online techniques of the Particle Into Liquid Sampler (PILS) for measurement of a suite of fine particle ionic compounds and a mist chamber (MC/IC) measurement of fine sulfate, and the longer time-integrated filter and multi-orifice impactor (MOI) measurements. Comparisons between identical PILS on two separate aircraft flying in formation showed that they were highly correlated (e.g., sulfate r(sup 2) of 0.95), but were systematically different by 10 +/- 5% (linear regression slope and 95% confidence bounds), and had generally higher concentrations on the aircraft with a low turbulence inlet and shorter inlet-to-instrument transmission tubing. Comparisons of PILS and mist chamber measurements of fine sulfate on two different aircraft during formation flying had an 3 of 0.78 and a relative difference of 39% +/- 5%. MOI ionic data integrated to the PILS upper measurement size of 1.3 pm sampling from separate inlets on the same aircraft showed that for sulfate, PILS and MOI were within 14% +/- 6% and correlated with an r(sup 2) of 0.87. Most ionic compounds were within f 30%, which is in the range of differences reported between PILS and integrated samplers from ground-based comparisons. In many cases, direct intercomparison between the various instruments is difficult due to differences in upper-size detection limits. However, for this study, the results suggest that the fine particle mass composition measured from aircraft agree to within 30-40%.

Published
2003

40. Préfaces d’antiromans: la contrefaçon préfacielle chez l’abbé Laurent Bordelon

Author

Herman,J, S.e.r.m.a.i.n.,.J. P., Angelet,C, Paiva Morais,A, Martin,M, Meding,T, Teixeira Anacleto,M, Riou, D, Rolla,C, Dionne,U, Coulet,H, Aragon,S, Vauterin,T, Kremer,N, Orsini,D, Pelckmans,P, Léger,B, Arrigoni,A, Peeters,K, Defrance,A, Zagamé,A, Goubier Robert,G, Charrier Vozel,M, Moser Verrey,M, Boulerie,F, Seguin,M, de Baere,B, Millet,B, van Dijk,S, Krief,H, Nuel,M, Kozul,M, MADONIA, Francesco Paolo, Herman,J, Sermain,J.-P., Angelet,C, Paiva Morais,A, Martin,M, Meding,T, Teixeira Anacleto,M, Riou, D, Rolla,C, Dionne,U, Coulet,H, Aragon,S, Vauterin,T, Kremer,N, Orsini,D, Pelckmans,P, Léger,B, Arrigoni,A, Peeters,K, Defrance,A, Zagamé,A, Goubier-Robert,G, Charrier-Vozel,M, Moser-Verrey,M, Boulerie,F, Seguin,M., de Baere,B, Millet,B, van Dijk,S, Krief,H, Nuel,M, Kozul,M, and Madonia, F.P.

Subjects
Bordelon, Settore L-LIN/03 - Letteratura Francese, contrefaçon préfacielle, Préface
Abstract

Il contributo intende dimostrare come le prefazioni degli "antiromanzi" dell'abate Lorent Bordelon mantengano il loro statuto testuale a dispetto dei procedimenti metafinzionali che vengono messi in atto dall'autore.

Published
2005

41. Allergic Contact Dermatitis from Aminoazobenzene in Tattoo

Author

Severino Persechino, Gripp, Alessandra Narcisi, G. Cortesi, C. Abruzzese, Giulianelli, Orsini D, Antonella Tammaro, and Francesca Romana Parisella

Subjects
medicine.medical_specialty, Allergy, Pathology, Triamcinolone acetonide, Erythema, business.industry, Patch test, Clinical manifestation, medicine.disease, Dermatology, medicine, medicine.symptom, business, Allergic contact dermatitis, Process of tattooing, Contact dermatitis, medicine.drug
Abstract

The tattoo phenomena is expanding rapidly among young people, all around the world: the process of tattooing involves the repetitive piercing of the skin with ink-filled needles, with the use of different types of pigment, like Azo ones. These azo-pigments are used for printing, painting of cars and staining of various consumer products. These pigments may contain titanium dioxide for lightening the shade, precursors and by-products of pigment synthesis, as well as diluents that are used for pigment suspension. We presented a clinical case of a 35 years old woman with 2 week history of itching allergic dermatitis presenting with heat, erythema and scaling appeared in the area of a colored tattoo on her shoulder 2 months after tattooing. Lesions where localized in the orange pigmented areas. We did a Patch test of SIDAPA series that resulted negative. Special series F.I.R.M.A. for tattoo was positive for aminoazobenzene-p 0.25% (++2) and phenylenediamine base-p 1%. Aminoazobenzene cause orange pigment. We performed local infiltration of triamcinolone acetonide, with temporary resolution of clinical manifestation.

Published
2013

45. The Arctic Summer Cloud Ocean Study (ASCOS) : overview and experimental design

Author

Tjernstrom, M., Leck, C., Birch, C. E., Bottenheim, J. W., Brooks, B. J., Brooks, I. M., Backlin, L., Chang, Y. -W, de Leeuw, G., Di Liberto, L., de la Rosa, S., Granath, E., Graus, M., Hansel, A., Heintzenberg, J., Held, A., Hind, A., Johnston, P., Knulst, J., Martin, M., Matrai, P. A., Mauritsen, T., Mueller, M., Norris, S. J., Orellana, M. V., Orsini, D. A., Paatero, J., Persson, P. O. G., Gao, Q., Rauschenberg, C., Ristovski, Z., Sedlar, Joseph, Shupe, M. D., Sierau, B., Sirevaag, A., Sjogren, S., Stetzer, O., Swietlicki, E., Szczodrak, M., Vaattovaara, P., Wahlberg, N., Westberg, M., Wheeler, C. R., Tjernstrom, M., Leck, C., Birch, C. E., Bottenheim, J. W., Brooks, B. J., Brooks, I. M., Backlin, L., Chang, Y. -W, de Leeuw, G., Di Liberto, L., de la Rosa, S., Granath, E., Graus, M., Hansel, A., Heintzenberg, J., Held, A., Hind, A., Johnston, P., Knulst, J., Martin, M., Matrai, P. A., Mauritsen, T., Mueller, M., Norris, S. J., Orellana, M. V., Orsini, D. A., Paatero, J., Persson, P. O. G., Gao, Q., Rauschenberg, C., Ristovski, Z., Sedlar, Joseph, Shupe, M. D., Sierau, B., Sirevaag, A., Sjogren, S., Stetzer, O., Swietlicki, E., Szczodrak, M., Vaattovaara, P., Wahlberg, N., Westberg, M., and Wheeler, C. R.

Abstract

The climate in the Arctic is changing faster than anywhere else on earth. Poorly understood feedback processes relating to Arctic clouds and aerosol-cloud interactions contribute to a poor understanding of the present changes in the Arctic climate system, and also to a large spread in projections of future climate in the Arctic. The problem is exacerbated by the paucity of research-quality observations in the central Arctic. Improved formulations in climate models require such observations, which can only come from measurements in situ in this difficult-to-reach region with logistically demanding environmental conditions. The Arctic Summer Cloud Ocean Study (ASCOS) was the most extensive central Arctic Ocean expedition with an atmospheric focus during the International Polar Year (IPY) 2007-2008. ASCOS focused on the study of the formation and life cycle of low-level Arctic clouds. ASCOS departed from Longyearbyen on Svalbard on 2 August and returned on 9 September 2008. In transit into and out of the pack ice, four short research stations were undertaken in the Fram Strait: two in open water and two in the marginal ice zone. After traversing the pack ice northward, an ice camp was set up on 12 August at 87 degrees 21' N, 01 degrees 29' W and remained in operation through 1 September, drifting with the ice. During this time, extensive measurements were taken of atmospheric gas and particle chemistry and physics, mesoscale and boundary-layer meteorology, marine biology and chemistry, and upper ocean physics. ASCOS provides a unique interdisciplinary data set for development and testing of new hypotheses on cloud processes, their interactions with the sea ice and ocean and associated physical, chemical, and biological processes and interactions. For example, the first-ever quantitative observation of bubbles in Arctic leads, combined with the unique discovery of marine organic material, polymer gels with an origin in the ocean, inside cloud droplets suggests the possi

Published
2014
Full Text
View/download PDF

46. The Arctic Summer Cloud Ocean Study (ASCOS): overview and experimental design

Author

Tjernstrom, Michael, Leck, Caroline, Birch, Cathryn, Bottenheim, Jan, Brooks, B., Brooks, Ian, Backlin, Leif, Chang, R., de Leeuw, Gerardus, Di Liberto, Luca, de la Rosa, Sara, Granath, E., Graus, M., Hansel, A., Heintzenberg, J., Held, A., Hind, A., Johnston, P., Knulst, Johan, Martin, M., Matrai, P., Mauritsen, T., Mueller, M., Norris, S., Orellana, M., Orsini, D., Paatero, J., Persson, P., Gao, Q., Rauschenberg, C., Ristovski, Zoran, Sedlar, J., Shupe, M., Sierau, B., Sirevaag, A., Sjogren, S., Stetzer, O., Swietlicki, Erik, Szczodrak, M., Vaattovaara, Petri, Wahlberg, N., Westberg, M., Wheeler, C., Tjernstrom, Michael, Leck, Caroline, Birch, Cathryn, Bottenheim, Jan, Brooks, B., Brooks, Ian, Backlin, Leif, Chang, R., de Leeuw, Gerardus, Di Liberto, Luca, de la Rosa, Sara, Granath, E., Graus, M., Hansel, A., Heintzenberg, J., Held, A., Hind, A., Johnston, P., Knulst, Johan, Martin, M., Matrai, P., Mauritsen, T., Mueller, M., Norris, S., Orellana, M., Orsini, D., Paatero, J., Persson, P., Gao, Q., Rauschenberg, C., Ristovski, Zoran, Sedlar, J., Shupe, M., Sierau, B., Sirevaag, A., Sjogren, S., Stetzer, O., Swietlicki, Erik, Szczodrak, M., Vaattovaara, Petri, Wahlberg, N., Westberg, M., and Wheeler, C.

Abstract

The climate in the Arctic is changing faster than anywhere else on earth. Poorly understood feedback processes relating to Arctic clouds and aerosol–cloud interactions contribute to a poor understanding of the present changes in the Arctic climate system, and also to a large spread in projections of future climate in the Arctic. The problem is exacerbated by the paucity of research-quality observations in the central Arctic. Improved formulations in climate models require such observations, which can only come from measurements in situ in this difficult-to-reach region with logistically demanding environmental conditions. The Arctic Summer Cloud Ocean Study (ASCOS) was the most extensive central Arctic Ocean expedition with an atmospheric focus during the International Polar Year (IPY) 2007–2008. ASCOS focused on the study of the formation and life cycle of low-level Arctic clouds. ASCOS departed from Longyearbyen on Svalbard on 2 August and returned on 9 September 2008. In transit into and out of the pack ice, four short research stations were undertaken in the Fram Strait: two in open water and two in the marginal ice zone. After traversing the pack ice northward, an ice camp was set up on 12 August at 87°21' N, 01°29' W and remained in operation through 1 September, drifting with the ice. During this time, extensive measurements were taken of atmospheric gas and particle chemistry and physics, mesoscale and boundary-layer meteorology, marine biology and chemistry, and upper ocean physics. ASCOS provides a unique interdisciplinary data set for development and testing of new hypotheses on cloud processes, their interactions with the sea ice and ocean and associated physical, chemical, and biological processes and interactions. For example, the first-ever quantitative observation of bubbles in Arctic leads, combined with the unique discovery of marine organic material, polymer gels with an origin in the ocean, inside cloud droplets suggests the possibility of primar

Published
2014

50. Flux creep after thermal neutron irradiation of uranium-doped oriented compacts of YBa2Cu3Ox.

Author

Luborsky, F. E., Arendt, R. H., Fleischer, R. L., Hart, H. R., Lay, K. W., Tkaczyk, J. E., and Orsini, D. A.

Subjects
CREEP (Materials), TEMPERATURE, NEUTRON irradiation, COPPER oxide
Abstract

Reports on changes in temperature spectrum of creep rate produced by slow neutron irradiation of yttrium-barium-copper oxide. Sample preparation and measurements; Experimental details; Result of the study.

Published
1991
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results